The package inserts of all statins suggest that the concomitant use of statins with niacin and fibrates should be avoided unless the potential benefits outweigh the risks; however, in patients who require fibrate therapy as well as substantial LDL-lowering 30% ; , there may be a modestly lower risk of adverse consequences when atorvastatin is combined with fenofibrate than other statin drug combinations. Extreme caution is necessary when using these combinations in patients with renal insufficiency because of their reduced clearance of drugs and metabolites and higher background risk of rhabdomyolysis. Drugs and foods known to affect the CYP3A4 system need to be used cautiously in patients treated with atorvastatin, lovastatin, or simvastatin because these agents are largely metabolized through that system. These combinations may result in a higher risk of statin-related adverse events as well as changes in therapeutic levels of both agents. There are poorly explained drug interactions with pravastatin and fluvastatin specifically acid-reducing agents ; as well, despite the fact that they largely do not rely on the CYP3A4 system for metabolism. The package insert of any statin should be consulted when prescribing such products for patients with complex regimens; the details and extent of these interactions are beyond the scope of this review. Provider should exercise caution in co-administering statin drugs with cyclosporine, certain anti-bacterial agents erythromycin, clarithromycin, metronidazole ; , certain anti-fungal agents itraconazole, fluconazole, ketoconazole ; , HIV protease inhibitors, rifampin, nefazodone, amiodarone, diltiazem, verapamil, danazol, phenytoin, diclofenac, zileuton, fluvoxamine, warfarin, digoxin, and large quantities more than 1 quart ; of grapefruit juice. Because many of these agents are prescribed for short courses, consideration of temporarily stopping a statin is reasonable as opposed to avoiding the use of a poten. KineMed Sciences Inc. discovery of new applications for multiple drug candidates and identification of alternative applications for certain therapeutic compounds formerly in our clinical stage pipeline ; Irish National Institute for Bioprocessing Research and Training glycosylation in CHO cell culture ; BrainCells Inc. discovery and development of drugs for the treatment of central nervous system disorders ; . Promising pipeline With 19% of our revenues invested in R&D, we continue to focus heavily on our product pipeline. We have the ambition to file at least one major compound per year on average over the coming years. Organon's focused pipeline is fully aligned with our growth strategy, which is to build on the strength of our existing franchises, return to growth in neuroscience, and expand into the field of biotechnology, for instance, posaconazole vs fluconazole or itraconazole prophylaxis. The primary efficacy analysis was based on the intention-to-treat approach, with the use of data from all patients who underwent randomization. First, the noninferiority of posaconazole as compared with fluconazole or itraconazole therapy was assessed. For our study, the incidence of proven or probable invasive fungal infection was assumed to be 8% or less with fluconazole or itraconazole prophylaxis.1 Therefore, using a cutoff level of significance of 4.87% for the final analysis in order to account for the interim analysis ; , we calculated that if the upper bound of the 95.13% confidence interval hereafter called the 95% CI ; for the difference between the incidence of proven or probable fungal infection for posaconazole and that for fluconazole or itraconazole was less than 4%, noninferiority would be demonstrated, and the superiority of posaconazole over fluconazole or itraconazole therapy could be assessed. The superiority of posaconazole would be established if the upper bound of the same 95% CI was negative. This two-step analysis allowed for an overall type 1 error rate of 0.05. We used the KaplanMeier method to evaluate time to death from any cause, time to death related to fungal infection, time to proven or probable fungal infection, time to first use of empirical antifungal therapy, and survival free from proven or probable invasive fungal infection. The survival benefit was assessed with the chi-square and logrank tests. All analyses except the noninferiority analysis were based on two-sided P values, with a two-sided P value of less than 0.05 considered to indicate statistical significance. The numbers of patients who would need to be treated to prevent one fungal infection and one death numbers needed to treat ; were calculated as described previously.29. The new law creates a grant program for states to create databases and enhance existing ones in hopes of ending the practice of doctor shopping by drug abusers seeking multiple prescriptions, for instance, itraconazole and alcohol. Before taking aricept, tell your doctor if you are taking any of the following medicines: atropine donnatal, and others belladonna; carbamazepine tegretol clidinium quarzan dexamethasone decadron dicyclomine bentyl glycopyrrolate robinul hyoscyamine anaspaz, cystospaz, levsin, and others mepenzolate cantil methantheline provocholine methscopolamine pamine ; , scopolamine transderm-scop phenobarbital luminal, solfoton phenytoin dilantin propantheline pro-banthine quinidine cardioquin, quinidex, quinaglute, others rifampin rifadin, rifamate, rifater a fungal antibiotic such as ketoconazole nizoral ; , fluconazole diflucan ; , or itraconazole sporanox or aspirin or other nsaids non-steroidal anti-inflammatory drugs ; such as ibuprofen motrin, advil ; , naproxen aleve, naprosyn ; , diclofenac voltaren ; , diflunisal dolobid ; , etodolac lodine ; , flurbiprofen ansaid ; , indomethacin indocin ; , ketoprofen orudis ; , ketorolac toradol ; , mefenamic acid ponstel ; , meloxicam mobic ; , nabumetone relafen ; , piroxicam feldene ; , and others.
Table i: optimal sampling time and windows after administration of itraconazole capsules and solution for 3 groups of patients and kamagra.
Using this method, the antifungal effects of terbinatine and itraconazole were evaluated in vitro.
Tier 1 Lowest Member Copayment GENERIC MEDICATIONS BRAND NAME GENERIC NAME ; Biaxin clarithromycin ; Biaxin XL clarithromycin, extended-release ; E.E.S. erythromycin ethylsuccinate ; E-Mycin erythromycin base ; EryPed erythromycin ethylsuccinate ; Erythrocin erythromycin stearate ; Ilosone erythromycin estolate ; Pediazole erythromycin sulfisoxazole ; Zithromax azithromycin ; Bactrim sulfamethoxazole trimethoprim ; Bactrim DS sulfamethoxazole trimethoprim ; Gantrisin tablet sulfisoxazole ; Pediazole sulfisoxazole erythromycin ; Septra sulfamethoxazole trimethoprim ; Septra DS sulfamethoxazole trimethoprim ; Cipro ciprofloxacin ; Cipro XR ciprofloxin ; PA ; Floxin ofloxacin ; Cleocin clindamycin ; 150mg, 300mg Capsule Flagyl metronidazole ; Flagyl ER metronidazole SA ; Hiprex methenamine ; Macrobid nitrofurantoin ; Macrodantin 50mg, 100mg nitrofurantoin ; Mandelamine methenamine ; Diflucan fluconazole ; Fulvicin P G griseofulvin, microsize ; Fulvicin U F griseofulvin, ultramicrosize ; Grifulvin-V Suspension griseofulvin, microsize ; Gris-Peg 125mg griseofulvin ultramicrosize ; Mycelex Troches clotrimazole ; Mycostatin nystatin ; Nystatin Suspension nystatin ; Nizoral ketoconazole ; Sporanox Capsule itraconazole ; Vermox mebendazole and ketoconazole.
Itraconazole tabsDr. Adler is the editor of California Pediatrician. He is the Vice Chair and Professor of Pediatrics at the Keck School of Medicine of the University of Southern California and the Associate Chair of the Department of Pediatrics and Academic Affairs and Director of Medical Education at Childrens Hospital Los Angeles, for example, itraconazole onychomycosis. Though our educational establishment has been slow to recognize it, boys have fallen seriously behind girls at all k-12 levels and lexapro. Table 28 Percentage of Individual Antimicrobials taken FOR Illness Antimicrobials FOR Illness Amoxicillin Amoxicillin & Clavulanic Acid Ampicillin Cefixime Cefprozil Ceftriaxone Cefuroxime Cephaclor Cephalexin Ciprofloxacin Doxycycline Erythromycin Gentamicin Itraconazole Metronidazole Norfloxacin Ofloxacin Penicillin Piperacillin & Tazobactam Sulfamethoxazole Sulfamethoxazole-Trimethoprim Tetracycline Ticarcillin & Clavulanic Acid Vancomycin Total Grouped Antimicrobials FOR Illness Fluoroquinolones Sulfamethoxazoles Penicillins Cephalosporins Lactams Frequency 40 2 11 Frequency 69 59 56 Percent of Named Antimicrobials 230 ; 17.39% 0.87% 4.78% Percent of Named Antimicrobials 230 ; 30% 25.65% 24.35. | Itraconazole dosagePRECAUTIONS General Prostate Cancer: Carcinoma of the prostate causes many of the same symptoms associated with BPH and the two disorders frequently co-exist. Carcinoma of the prostate should therefore be ruled out prior to commencing therapy with CARDURA XL. Cataract Surgery: Intraoperative Floppy Iris Syndrome IFIS ; has been observed during cataract surgery in some patients on or previously treated with alpha1 blockers. This variant of small pupil syndrome is characterized by the combination of a flaccid iris that billows in response to intraoperative irrigation currents, progressive intraoperative miosis despite preoperative dilation with standard mydriatic drugs, and potential prolapse of the iris toward the phacoemulsification incisions. The patient's surgeon should be prepared for possible modifications to their surgical technique, such as the utilization of iris hooks, iris dilator rings, or viscoelastic substances. There does not appear to be a benefit of stopping alpha1 blocker therapy prior to cataract surgery. Gastrointestinal Disorders: As with any other non-deformable material, caution should be used when administering CARDURA XL to patients with preexisting severe gastrointestinal narrowing pathologic or iatrogenic ; . There have been rare reports of obstructive symptoms in patients with known strictures in association with the ingestion of another drug in this non-deformable extended release formulation. Markedly increased GI retention times, as may occur in patients with chronic constipation, can increase systemic exposure to doxazosin and thereby potentially increase adverse reactions. Patients with Hepatic Impairment: CARDURA XL should be administered with caution to patients with evidence of mild or moderate hepatic dysfunction see CLINICAL PHARMACOLOGY; Pharmacokinetics in Special Populations ; . Since there is no clinical experience in patients with severe hepatic dysfunction, use in these patients is not recommended. Drug Interactions: No in vivo drug interaction studies were conducted with CARDURA XL see CLINICAL PHARMACOLOGY; Drug-Drug Interactions ; . In vitro studies suggest that doxazosin is a substrate of CYP3A4. Caution should be exercised when concomitantly administering a potent 3A4 inhibitor, such as atanazavir, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole with CARDURA XL. Pharmacodynamic interactions between CARDURA XL and anti-hypertensive medications or other vasodilating agents have also not been determined. Patients with Coronary Insufficiency: Patients with congestive heart failure, angina pectoris, or acute myocardial infarction within the last 6 months were excluded from the Phase 3 studies. If symptoms of angina pectoris should newly appear or worsen, CARDURA XL should be discontinued. Information for Patients Patients should be told about the possible occurrence of symptoms related to postural hypotension, such as dizziness or syncope, when beginning therapy or when increasing dosage strength of CARDURA XL. Patients should be cautioned about driving, operating machinery, or performing hazardous tasks during this period, until the drug's effect has been determined and loratadine. Patients on Antabuse. Although some publications recommend against the use of INH for persons taking Antabuse, there is no strong evidence that Antabuse and INH, when taken together, cause a serious health risk. Therefore, INH should be given when indicated for persons on Antabuse. Patients on Remicade Infliximab ; . Providers should screen patients for LTBI or disease before prescribing Remicade Infliximab ; . Active tuberculosis may develop soon after initiation of treatment with Remicade Infliximab ; . Other drug interactions. INH has been reported to inhibit the metabolism of the following drugs: anticonvulsants, haldoperidol, ketoconazole, theophylline and warfarin. Thus, INH may need to be introduced slowly and or the dose of these drugs adjusted to prevent toxicity. The patient's private physician must be consulted in these situations. Rifamycins are known to induce certain P450 enzymes in the liver rifampin more than rifabutin ; , and may accelerate the metabolism of certain drugs such as hormonal contraceptives, ketoconazole, fluconazole, itraconazole, beta-blockers, calcium channel blockers, cardiac glycosides, diazepam, hypoglycemic agents sulfonylureas ; , some antibiotics, corticosteroids, narcotics including methadone ; , anti-coagulants, anti-convulsants, tricyclic antidepressants, theophylline, and AZT. Rifampin is contraindicated in patients on all protease inhibitors PIs ; and nonnucleoside reverse transcriptase inhibitors NNRTIs ; . Rifabutin is contraindicated with ritonavir a PI ; , hard-gel saquinavir a PI ; , and delavirdine a NNRTI. IMITREX. 14 IMPLANON . 32 INCRELEX VIAL . 19 indapamide . 24 INDERAL LA. 21 indomethacin8, 13 INFLAMASE MILD 0.125% DROPS . 36 INTAL INHALER . 38 intralipid 10% . 42 INTRON A . 33 INVANZ . 10 INVERSINE. 23 ipratropium br 0.02% soln. 39 ipratropium spray . 43 isoniazid. 14 ISOPTO CARBACHOL 1.5% DROPS . 36 ISOPTO HOMATROPIN E 2% DROPS . 37 isosorbide dinitrate . 24 isosorbide mononitrate . 24 isradipine . 22 ISTALOL 0.5% EYE DROPS36 itraconazole. 13 J jantoven . 20 junel tablet. 31 K k effervescent 25 meq tablet. 40 k + potassium 20 meq packet. 40 KADIAN . 7 KALETRA ORAL SOLUTION. 18 KAON ELIXIR . 40 kariva 28 day tablet . 31 KEPPRA. 11 KERALAC . 26 keratol 40 cream . 26 keratol 40 gel . 26 KETEK . 9 and macrodantin. |
Of the 30 pharmacies tested, 24 sold the drug to the teenager with little or no consultation involved and miconazole and itraconazole, for instance, itraconazole intravenous.
Reddy's laboratories nyse: rdy ; is an emerging global pharmaceutical company with proven research capabilities!
Warfarin interaction can be explained by inhibition of the CYP2C9mediated metabolism of S-warfarin. Minor inhibition of the CYP1A2mediated metabolism of R-warfarin by gemfibrozil may also contribute to the interaction. In one case report, gemfibrozil has been reported to interact with glyburide, resulting in hypoglycemia Ahmad, 1991 ; . Glyburide is extensively metabolized in the liver, with CYP2C9 being the predominant enzyme Brian, 2000 ; . Our in vitro inhibition studies suggest that inhibition of CYP2C9 activity by gemfibrozil is the likely mechanism of the gemfibrozil-glyburide interaction. Gemfibrozil can interact with several statins, such as lovastatin Pierce et al., 1990 ; and simvastatin Tal et al., 1997 ; , resulting in an increased incidence of myopathy and rhabdomyolysis. The exact mechanism that underlies these drug interactions is unknown. However, it was found recently that gemfibrozil markedly increases the plasma concentrations of active simvastatin acid and lovastatin acid, whereas the concentrations of parent simvastatin and lovastatin are not altered Backman et al., 2000; Kyrklund et al., 2001 ; . Parent simvastatin and lovastatin are metabolized mainly by CYP3A4 Vickers et al., 1990 ; . Because gemfibrozil is not a CYP3A4 inhibitor, the gemfibrozil-simvastatin and gemfibrozil-lovastatin interactions cannot be explained by inhibition of the CYP3A4-mediated simvastatin and lovastatin metabolism, as is the case with itraconazole-lovastatin and itraconazole-simvastatin interactions. The present finding that gemfibrozil strongly inhibits the activity of CYP2C9 and, to a lesser extent, that of CYP2C19 and CYP1A2 raises the possibility that some of these CYP isoforms might be involved in the metabolism of simvastatin and lovastatin acid. However, inhibition of some other pathways that regulate the levels of the statin acids by gemfibrozil cannot be ruled out. To conclude, the present in vitro study demonstrates that gemfibrozil in clinically relevant concentrations is a potent inhibitor of CYP2C9 and a modest inhibitor of CYP2C19 and CYP1A2. However, the activity of CYP2A6, CYP2D6, CYP2E1, and CYP3A4 is not affected by gemfibrozil. Inhibition of CYP2C9 seems to explain the observed interactions of gemfibrozil with warfarin and glyburide. Also, because other substrates of CYP2C9 with a narrow therapeutic.
From the Departments of Dermatology, Geneva University Medical School, Geneva, Switzerland Drs Prins, Viard, Saurat, and French University of Miami School of Medicine, Miami, Fla Drs Kerdel and Trent University of New Mexico, Albuquerque Drs Padilla and Flynn University of Bern Medical School, Bern, Switzerland Dr Hunziker University Tor Vergata, Rome, Italy Dr Chimenti Apotech Corporation, Epalinges, Switzerland Dr Mauri and University of Pennsylvania, Philadelphia Drs Margolis and French ; . A list of other participants in the TEN-IVIG Study group appears at the end of this article.
Women who have recently given birth may have been treated with antibiotics for a Cesarean birth or for GBS Group B bhemolytic Streptococcal infection ; . Treatment with antibiotics destroys some of the body's helpful bacteria as well as harmful bacteria ; . One function of the good bacteria is to keep the yeast from overgrowing. If you have been on antibiotics recently, you can take acidophilus to help reestablish the good bacteria in your body. Acidophilus can be found in the refrigerated case of your local health food store, and some supermarkets also carry it in their dairy sections. The container label will state how much and how often to take the acidophilus. Remember to keep the acidophilus refrigerated. When a baby develops thrush, there are visible white patches in the baby's mouth, 14 especially on the tongue. Of course the baby's tongue can look white from milk. Try to wipe off the white substance with a wet washcloth. If it is yeast, it will not wipe off. Sometimes a baby can have a yeast overgrowth but not yet have visible white growth in the mouth. If a baby has a yeast infection in the diaper area, the baby's bottom is red and irritated. Sometimes for people with dark skin, the infected area may appear darker than their normal skin color, for example, ketoconazole itraconazole. 607, 33101 Tampere, Finland 228 Pang X-L, Vesikari T. Human astrovirusassociated gastroenteritis in children under 2 years of age followed prospectively during a rotavirus vaccine trial. Acta Paediatr 1999 May; 88 5 ; : 532-6. 25 ref, Eng. University of Tampere, Medical School, PO Box 607, 33101 Tampere, Finland "This study evaluated the clinical significance of human astrovirus-associated gastroenteritis in young children in the community. Placebo- n 1207 ; and rhesus rotavirus tetravalent RRV-'I'V ; vaccine- n 1191 ; recipient children were followed from 2 mo to age. Stool specimens from 1528 episodes of acute gastroenteritis 805 in the placebo group and 723 in the RRV-TV vaccine group ; were tested for astrovirus with a sensitive reverse transcription-polymerase chain reaction RT-PCR ; assay and positive results were confirmed by Southern hybridization using probes specific for astrovirus serotypes 1 and 2. Astroviruses were detected in 144 9% ; episodes of gastroenteritis; 92% of the findings were serotype 1 and 6% were serotype 2. The astrovirus peak season was in winter. Of the 102 children who had gastroenteritis with astrovirus as the only diarrhoea virus in the stools, 72% had watery diarrhoea, 59% had vomiting, 26% had fever, 5% needed oral rehydration and 3% were hospitalized. Overall, the clinical severity of astrovirus gastroenteritis was much lower than that of rotavirus gastroenteritis. RRV-TV rotavirus vaccine did not protect against astrovirus gastroenteritis. It is concluded that astroviruses are common causative agents in acute gastroenteritis in young children, but the symptoms of astrovirus gastroenteritis are usually mild and the illness is therefore only of minor clinical significance." 229 Parashar UD, Bresee JS, Gentsch JR, Glass RI. Rotavirus. Emerging Infect Dis 1998 OctDec; 4 ; : 561-70. 52 ref, Eng. Viral Gastroenteritis Section, Mail Stop G04, Centers for Disease Control and Prevention, 1600 Clifton Road, NE, Atlanta, GA 30333, USA 230 Patra FC, Majumder RN, Eeckels R, Desjeux J-F, Mahalanabis D. Sacolene in cholera: a double blind randomized controlled trial. Scand J Infect Dis 1999; 31 2 ; : 151-4. 22 ref, Eng. Society for Applied Studies, 108 Manicktala Main Road, Flat 3 21, Calcutta 700054, India "Methylated casein Sacolene ; , a diarrhoea remedy used in Europe, has shown an antisecretory effect in cholerainduced secretion in animals and benefit in diarrhoea in humans. In this placebo controlled trial Sacolene was evaluated in 78 male adults with severe cholera who, after initial i.v. therapy received Sacolene or placebo, 4 g at start and 2 g 4 hourly until cessation of diarrhoea, along with oral rehydration therapy and repeat i.v. therapy if indicated. No antibiotics were given during the study. The purging rate and diarrhoea duration were similar in the 2 groups. The proportion of patients requiring repeat and kamagra.
Ition.4 Both types of drug have favourable pharmacokinetic profiles in cerebrospinal fluid and bone.4 In one report, a nodule on a finger was treated with surgical excision and three antifungals, but after a month another lesion appeared in the left arm with no healing of the finger lesion. In this case, treatment with co-trimoxazole was initiated on diagnosis of a Nocardia superinfection, and after 11 days both lesions had improved. This suggests that sulphonamides might be effective in treating this infection.5 Quinolones have a broad spectrum of activity as inhibitors of DNA gyrase, type 2 topoisomerase, which is present in prokaryotes and eukaryotes. The presence of high levels of topoisomerases I and II has been reported in pathogenic fungi.6 Although they are inapplicable as sole antifungal agents, quinolones augment the activity of amphotericin B and azoles.7, 8 For example, in a murine model study of candidiasis, similar survival rates were demonstrated in mice treated with fluconazole alone 80 mg kg day and in those treated with fluconazole 40 mg kg day ; and ciprofloxacin.8 The aim of the present study was to investigate the in vitro activity of quinolones and sulfadiazine, either alone or in combination with amphotericin B or itraconazole, as well as!
I bought some jolt cola from the local market, it’ s powerfull, but nothing close to a good dose of caffeine pills.
Interactions: Rifabutin is a CYP 3A3 4 enzyme inducer. Increased effect toxicity: Rifabutin is increased by Indinavir and Ritonavir. Fluconazole increases Rifabutin concentrations. Decreased effect: Rifabutin may decrease plasma concentrations of Verapamil, methadone, digoxin, cyclosporine, corticosteroids, oral anticoagulants, Theophylline, barbiturates, chloramphenicol, itraconazole, Ketoconazole, oral contraceptives, Quinidine, protease inhibitors Indinavir, Nelfinavir, Ritonavir, Saquinavir ; and nonnucleoside reverse transcrptase inhibitors and clarithromycin. Adverse Reactions: The most common adverse reactions 10% ; include: rash, discolored urine, neutropenia, and leukopenia. Less common adverse reactions 1% to 10% ; include: headache, nausea, vomiting, diarrhea, abdominal pain, anorexia, flatulence, anemia, thrombocytopenia, increased AST ALT and myalgia. Costs and Monitoring: Monitoring includes periodic liver function tests and CBC with differential. Cost of therapy is $ 11.62 per day.
Drug interaction" is often viewed with the negativity of "adverse drug reaction." It's true that some drug interactions are potentially lethal, but drug interactions are often used therapeutically. This workshop will address the hows and whys of drug interactions good and bad. We will consider pharmacokinetic and pharmacodynamic mechanisms with basic explanations of key concepts of pharmacokinetics and pharmacodynamics. We will also discuss the role of genetics in drug interactions pharmacogenomics ; . The workshop will include common examples of interactions between drugs, with foods, and with dietary supplements an area of particular interest of the workshop leader ; . We will discuss absorption interactions and ways to avoid them. We will discuss interactions that involve drug distribution and how this occurs. Mechanisms of metabolic interactions will be covered in considerable depth. We will discuss the cytochrome P-450 enzyme system and various isozymes that affect drug metabolism in humans. We will also cover other enzyme systems. We will discuss drug interactions that involve drug excretion. We will discuss how metabolic interactions may be affected by genetic factors. As time permits, we will touch on protein carriers that affect drug metabolism.
Astellas Pharma Inc. and Consolidated Subsidiaries.
Serious cardiovascular adverse events including death, ventricular tachycardia , and torsades de pointes have occurred in patients taking itraconazole concomitantly with cisapride.
Approved noxafil r ; posaconazole ; oral suspension for the treatment of oropharyngeal candidiasis opc ; , including infections refractory to itraconazole and or.
And duration of the drug and the potential for drug resistance 7 ; . Cross-resistance to other azole antifungal agents is common but not universal and is not associated with cross-resistance to polyene antibiotics, such as amphotericin B and nystatin 9 ; . Unlike the azole drugs that exert their effect by inhibition of fungal cytochrome P450 enzymes, the polyene antifungals act by binding to ergosterol, in the fungal cell membrane. Resistance to the polyene antifungals remains an uncommon event among Candida isolates. The polyenes still have reliable activity against most of the Candida species, except C lusitaniae, which is often intrinsically resistant. In addition, reduced susceptibility appears common among isolates of C glabrata 9, 10 ; . The susceptibility of Candida species to Cicloproxolamine has been shown to be similar to that of the imidazoles 11 ; . The emergence of non-albicans Candida species is also clearly a concern. Prototheca, a genus of achlorophyllic algae, is a rare cause of opportunistic infections in humans. Polyene antifungals remain the most effective drugs for eradicating Prototheca infections. Azole antifungals may also be used with more localized infections, itraconazole being the most effective drug of this class 12 ; . Of the three Prototheca isolates 66.6% ; two were appropriately empirically treated, one with an imidazole, and the other with a triazole. The other was in the group inappropriately empirically treated with antibiotics. Recently, the number of reports of the isolation of nonneoformans Cryptococcus species from clinical specimens and opportunistic infection by this species has been increasing. This basidiomycetous yeast is known to be sensitive to the polyene antifungals and to vary in resistance to azoles such as fluconazole and itraconazole. In view of this possible resistance, the use of polyene antifungals for the treatment of C albidus associated vaginitis in this study would have been the more appropriate drug of choice 13 ; . Antifungal therapy was inappropriately prescribed in 54% of culture negative cases. Such unnecessary use of anti.
© 2007